본문바로가기
Ciropan Tab.
Category
ETC
Indication(s)·Usage
    • 1. Effective strains
      Escherichia coli, Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus (Indole positive and negative), Pseudomonas, Neisseria, Acinetobacter, Streptococcus, Chlamydia, Staphylococcus, bacteroidosis

    • 2. Indication(s)
      • - Respiratory infection, community acquired infection pneumonia except acute bronchitis
      • - Ear, nose, throat infection (pharyngitis, tonsillitis, laryngitis, otitis externa, except preoperative use against bone-metastasized chronic otitis media and chronic cholesteatomatous otitis media)
      • - Bacterial prostatitis, acute uncomplicated cystitis, acute pyelonephritis, complicated urinary tract infection
      • - Gonococcal cervicitis and gonococcal urethritis
      • - Gastrointestinal infection
      • - Biliary tract infection
      • - Skin and soft tissue infection and wound
      • - Bone, joint infection
      • - Gynecologic infection (except vaginal infection)
      • - Peritonitis
      • - Dacryocystitis, hordeolum, anophthalmia

    Fluoroquinolones including this drug are related to serious adverse events, so administer to patients who have no other treatment methods in acute bacterial sinusitis, chronic bronchitis, acute bacterial aggravation of chronic obstructive pulmonary disease, simple urinary tract infection, and acute otitis media.

Effective components
Ciprofloxacin Hydrochloride 291 mg (ciprofloxacin 250 mg)

Active ingredient(s) and Contents

  • Effective components

    • Ciprofloxacin Hydrochloride 291 mg (ciprofloxacin 250 mg)
  • Other

    • Sodium Starch Glycolate, Polyethylene Glycol 6000, Titanium Oxide, Corn starch, Sodium Starch Glycolate, Magnesium Stearate, Diacetylated Monoglycerides, Low Substituted Hydroxypropyl cellulose, Hypromellose, Hydroxypropyl cellulose

Dosage and administration

  • (tablets)

    • 1.Orally administer 250 to 500 mg of ciprofloxacin twice daily between meals in adults. In the case of severe combined infection, this drug can be increased to 750 mg twice daily.In case of acute infection, it is usually treated for 5 to 10 days, and is administered for at least 3 more days after symptoms subside.

    • 2.Patients with renal impairment
      • 1) creatinine clearance > 50 mL/min: Administer the usual maintenance dose.
      • 2) 30 to 50 mL/mn: Administer 250 to 500 mg twice daily.
      • 3) 5 to 29 mL/min: Administer 250 to 500 mg every 18 hours.
      • 4) hemodialysis patients or peritoneal dialysis patients: Administer 250 to 500 mg once daily after dialysis.
      • 5) If only serum creatinine is known, the creatinine clearance can be calculated using the following calculation formula.
        • Male: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)}
        • Female: 0.85 × the value of male
      • 6) In the case of severe infection, even if there is a severe renal impairment, the dose may be increased to 750 mg, but the patient's condition should be carefully observed after administration.

        The dose may be adjusted depending on the patient’s symptoms.

Storage and handling

  • Well-closed container, keep at room temperature (1~30°C)
  • 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
    463-400 Korea [13494]
  • Copyright(c) SK chemicals. All Rights Reserved.

Ethical Management

Site go

GO